Bionano Genomics, Inc.
BNGO · XNASCIK 1411690fmd_1T9A4QQ3CY8AWBMDFJSY18K9SYManufacturing · Laboratory Analytical InstrumentsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 12 | 10 | 9 | 18 | 28 | 36 | 31 | 29 |
| Cost of revenue | 6 | 9 | 7 | 6 | 14 | 22 | 27 | 30 | 15 |
| Gross profit | 3 | 3 | 3 | 3 | 4 | 6 | 10 | 0 | 13 |
| Realized investment gains (losses) | – | – | – | – | 0 | (0) | (0) | (0) | 0 |
| Research and development | 12 | 9 | 9 | 10 | 22 | 49 | 54 | 25 | 11 |
| Selling, general and administrative | 14 | 14 | 20 | 31 | 58 | 89 | 93 | 52 | 35 |
| Operating income | (23) | (20) | (26) | (39) | (77) | (132) | (215) | (104) | (33) |
| Interest expense | 1 | 1 | 2 | 3 | 1 | 0 | 5 | – | – |
| Interest and investment income | – | – | – | – | 0 | 2 | 3 | 2 | 1 |
| Other non-operating income (expense) | (0) | 2 | (4) | (3) | (1) | 1 | (17) | (8) | 7 |
| Income before taxes | (23) | (18) | (30) | (41) | (78) | (131) | (232) | (112) | (26) |
| Income tax expense | 0 | 0 | 0 | 0 | (6) | 2 | 0 | 0 | 0 |
| Net income from continuing operations | (23) | (18) | (30) | (41) | (72) | (133) | (232) | (112) | (26) |
| Net income | (23) | (18) | (30) | (41) | (72) | (133) | (232) | (112) | (26) |